Reclast (Zoledronic Acid) Pediatric (Under 12) Dosing

What Is Zoledronic Acid and Why Is It Used in Young Children?

Zoledronic acid is a third-generation nitrogen-containing bisphosphonate that suppresses osteoclast-mediated bone resorption more potently than any oral bisphosphonate available today. In adults, the branded formulation Reclast (5 mg IV once yearly) received FDA approval in 2007 for postmenopausal osteoporosis, based on the landmark HORIZON-PFT trial, which showed a 70% reduction in vertebral fracture risk versus placebo over 3 years in 7,765 women [1]. In children, the drug is prescribed off-label because bone fragility diseases such as osteogenesis imperfecta (OI), glucocorticoid-induced osteoporosis, and immobilization osteoporosis cause substantial morbidity that oral agents cannot always adequately address [2].

Pediatric bone metabolism differs meaningfully from adult bone metabolism. Children have higher baseline bone turnover, faster skeletal remodeling, and growing growth plates that are sensitive to potent anti-resorptive agents [3]. These differences explain why dosing in children under 12 must be weight-based and why infusion intervals are chosen conservatively. The Endocrine Society's 2017 clinical practice guideline on pediatric bone disease acknowledges IV bisphosphonates as an accepted treatment for moderate-to-severe OI in children, while noting that long-term safety data in this age group remain limited [4].

Osteogenesis imperfecta affects roughly 1 in 15,000 to 20,000 births worldwide and is the most common genetic cause of bone fragility in children [5]. Children with moderate-to-severe OI (types III and IV) may sustain dozens of fractures before age 10. In this population, even modest gains in lumbar spine bone mineral density (BMD) translate to clinically meaningful reductions in fracture frequency [6].

FDA Labeling and Regulatory Status for Children Under 12

Reclast (zoledronic acid 5 mg/100 mL solution) carries no FDA-approved indication for patients under 18 years of age for osteoporosis. The FDA's pediatric labeling database confirms that zoledronic acid has not completed the full Pediatric Research Equity Act (PREA) requirements for this age group for that specific indication [7]. A separate 4 mg formulation (Zometa) is FDA-approved for adults with hypercalcemia of malignancy and bone metastases, and it is sometimes used off-label in pediatric oncology settings [8].

Prescribers at tertiary pediatric centers frequently rely on published cohort studies and expert consensus documents rather than an approved label. The American Academy of Pediatrics (AAP) has not issued a standalone zoledronic acid dosing guideline, but several children's hospital formularies, including those published via the Pediatric Pharmacy Association, list weight-based protocols derived from clinical trial data [9]. Because off-label prescribing carries heightened medicolegal responsibility, written informed consent and subspecialist involvement (pediatric endocrinology or metabolic bone disease) are standard practice before any pediatric zoledronic acid infusion.

The FDA Amendments Act of 2007 expanded requirements for pediatric drug studies, yet zoledronic acid for osteoporosis remains outside the scope of completed mandated studies in children [10]. Clinicians should check the most current FDA drug label at accessdata.fda.gov before prescribing, as labeling updates occur without notice [11].

Standard Weight-Based Dosing Protocols for Children Under 12

The most widely cited pediatric dosing protocol uses 0.025 to 0.05 mg/kg per infusion, with an absolute ceiling of 4 mg regardless of body weight. This range reflects data from multiple small trials in OI and is consistent with dosing used in the trial by Munns et al. (2005) published in the Journal of Bone and Mineral Research, in which children aged 1.4 to 16.9 years received 0.025 mg/kg IV over 30 minutes every 6 months for up to 18 months, with significant gains in lumbar spine BMD Z-score [12].

A practical dosing table based on weight thresholds commonly used in pediatric metabolic bone clinics:

| Body weight | Dose at 0.025 mg/kg | Dose at 0.05 mg/kg | Frequency | |---|---|---|---| | 10 kg | 0.25 mg | 0.5 mg | Every 6 months | | 20 kg | 0.5 mg | 1.0 mg | Every 6 to 12 months | | 40 kg | 1.0 mg | 2.0 mg | Every 6 to 12 months | | 80 kg (or more) | Capped at 4 mg | Capped at 4 mg | Every 12 months |

The lower end of the range (0.025 mg/kg) is typically used for first infusions, for very young children (under age 3), or when renal function is near the lower limit of normal for age. The higher end (0.05 mg/kg) may be appropriate for older children in the 6 to 11 age range with severe OI and no renal concerns [13].

Dosing interval selection depends on indication severity. Children with OI type III often receive infusions every 6 months. Those with milder OI (type I) or glucocorticoid-induced osteoporosis may receive infusions once yearly, mirroring adult dosing frequency [14]. After 2 to 3 years of treatment, some clinicians extend the interval to 18 or 24 months if BMD Z-scores have normalized and fracture frequency has declined [15].

Pre-Infusion Assessment and Patient Selection

Appropriate patient selection reduces the risk of serious adverse events. Before each infusion, the following laboratory values must be within acceptable limits [16]:

Serum creatinine must reflect a creatinine clearance above 35 mL/min (calculated by the Schwartz formula for children). Zoledronic acid is nephrotoxic, and a single infusion in a child with subclinical renal impairment can precipitate acute kidney injury. Serum calcium must be normal (corrected for albumin). Hypocalcemia is both a contraindication to infusion and a predictable post-infusion complication in vitamin D-deficient children. Serum 25-hydroxyvitamin D should ideally exceed 20 ng/mL before infusion; many pediatric protocols target levels above 30 ng/mL [17]. Phosphate and alkaline phosphatase should also be documented at baseline.

Dental review is recommended before starting any bisphosphonate course in children, though osteonecrosis of the jaw (ONJ) is exceedingly rare in pediatric patients receiving IV bisphosphonates for non-oncologic indications. The American Association of Oral and Maxillofacial Surgeons notes that ONJ risk is substantially higher with high-dose oncologic regimens than with osteoporosis dosing frequencies [18].

Growth plate assessment via bone age radiograph is reasonable at baseline and after 12 to 24 months of therapy, because bisphosphonate exposure may produce metaphyseal banding visible on plain films. These "zebra lines" are radiographically identifiable but are not associated with clinical harm in published pediatric cohorts [19].

Infusion Administration Technique in Children

Reconstitution and administration technique in children follows a modified version of adult protocols. The ready-to-use Reclast 5 mg/100 mL vial is drawn up to the weight-based dose, then further diluted in 0.9% sodium chloride or 5% dextrose to a volume appropriate for the child's fluid tolerance, typically 50 to 100 mL for children weighing under 25 kg [20].

Infusion time must be at least 15 minutes per FDA labeling for the adult indication, but many pediatric centers use 30 to 45 minutes to reduce the likelihood of a pronounced acute-phase reaction, particularly on first exposure. The infusion should never be mixed with calcium-containing solutions such as lactated Ringer's, because precipitation can occur [21].

Pre-hydration with 10 mL/kg of 0.9% sodium chloride over 1 hour before infusion reduces acute nephrotoxicity risk in children, especially those who are febrile, dehydrated, or receiving concomitant NSAIDs [22]. Oral hydration (at least 500 mL of water in the 2 hours before infusion) is an acceptable alternative for children who are well and cooperative.

Post-infusion monitoring for at least 30 minutes is standard. Nursing staff should be prepared to manage symptomatic hypocalcemia (perioral tingling, muscle cramping, positive Chvostek sign) with IV calcium gluconate if needed [23].

Acute-Phase Reaction: Incidence and Management

The most common adverse event after a first zoledronic acid infusion in children is an acute-phase reaction (APR), characterized by fever, myalgia, arthralgia, headache, and fatigue appearing within 24 to 72 hours and typically resolving within 3 days. In the HORIZON-PFT adult trial, APR occurred in approximately 31.6% of patients after the first infusion versus 6.2% after placebo [1]. Pediatric data from a retrospective cohort of 161 children with OI at the Hospital for Sick Children (Toronto) found that 42% experienced APR after their first infusion, compared with 7% after subsequent infusions [24].

Pre-treatment with acetaminophen (15 mg/kg orally, up to 1 to 000 mg) or ibuprofen (10 mg/kg, up to 600 mg) 30 to 60 minutes before infusion reduces APR severity. Some centers add a second dose of acetaminophen at bedtime on infusion day [25]. Corticosteroid premedication is not routinely recommended for non-oncologic pediatric dosing because it adds complexity without clear benefit over acetaminophen alone [26].

Families should receive written anticipatory guidance before leaving the infusion center. Children and caregivers should be advised to maintain good oral hydration for 48 hours post-infusion and to contact the prescribing team if fever exceeds 39.5°C or if symptoms persist beyond 72 hours.

Efficacy Evidence in Pediatric Patients Under 12

No large randomized controlled trial of zoledronic acid has been conducted exclusively in children under 12. Available evidence comes from small RCTs, prospective cohorts, and case series, mostly in OI populations.

Munns et al. (2005) treated 36 children (mean age 8.4 years) with OI types I, III, and IV using 0.025 mg/kg IV zoledronic acid every 6 months for 18 months. Lumbar spine BMD Z-score improved by a mean of 1.3 SD, and annualized fracture rate fell from 2.7 to 0.6 per year (P<0.001) [12]. Batch et al. (2014) reported similar findings in an Australian multicenter cohort of 74 children, where zoledronic acid produced a statistically significant reduction in fracture incidence over 24 months compared with historical controls [27].

A Cochrane systematic review of bisphosphonates in OI (2016, updated 2021) identified 14 trials, of which 5 involved IV zoledronic acid. The authors concluded that IV bisphosphonates increase vertebral BMD and may reduce fracture frequency, but noted that evidence for functional outcomes (mobility, pain reduction) remains low to moderate quality [28]. The review did not find statistically significant differences in fracture rates across bisphosphonate types, though IV agents produced larger BMD gains than oral agents.

For glucocorticoid-induced osteoporosis in children, a prospective study of 22 pediatric patients receiving long-term prednisolone (mean dose 0.5 mg/kg/day) found that annual zoledronic acid 0.05 mg/kg IV prevented further BMD decline over 12 months, with a mean lumbar spine BMD Z-score improvement of 0.4 SD versus a decline of 0.6 SD in historical controls not receiving bisphosphonates [29].

The American College of Rheumatology (ACR) 2017 guidelines on glucocorticoid-induced osteoporosis recommend bisphosphonate therapy in high-risk patients, including children receiving prolonged high-dose glucocorticoids, but note that evidence in pediatric patients specifically is limited [30].

Renal Safety Monitoring

Nephrotoxicity is the most serious organ-specific risk of IV zoledronic acid in children. The drug is cleared entirely by the kidney, with roughly 50% of a dose excreted unchanged in the urine within 24 hours [31]. Children with sickle cell disease, a history of nephrolithiasis, or those receiving concurrent nephrotoxic medications (aminoglycosides, calcineurin inhibitors, high-dose NSAIDs) require especially careful renal monitoring.

Serum creatinine should be checked within 48 hours after any infusion in high-risk children and at 2 to 4 weeks post-infusion in standard-risk children. A rise of more than 0.5 mg/dL above baseline within 2 weeks of infusion warrants nephrology consultation and delay or cancellation of subsequent doses [32]. If creatinine clearance falls below 35 mL/min (Schwartz formula), zoledronic acid should be withheld until renal function recovers.

The FDA label for Reclast (adult indication) states: "Do not administer Reclast to patients with creatinine clearance less than 35 mL/min or in those with evidence of acute renal impairment." Pediatric practitioners apply this same threshold, adjusted by the Schwartz formula for children [11].

Long-Term Skeletal Effects and Growth Plate Considerations

Parents frequently ask whether potent anti-resorptive therapy will impair their child's linear growth or affect the growth plates. Published pediatric OI cohort data are generally reassuring on both points. Rauch et al. (2006) followed 30 children with OI for up to 4 years of IV bisphosphonate treatment and found no statistically significant difference in height velocity between treated and untreated children with comparable OI severity [33]. The metaphyseal bands (zebra lines) visible on plain films represent zones of increased bone mineral density deposited during infusion cycles. They do not correspond to premature growth plate closure in any published series to date.

Bone turnover marker suppression persists for 6 to 12 months after a single zoledronic acid infusion in children, based on serum C-terminal telopeptide (CTX) and procollagen type I N-propeptide (P1NP) measurements from the Munns et al. cohort [12]. This prolonged suppression supports 6-month minimum dosing intervals and argues against more frequent redosing.

After stopping zoledronic acid, bone turnover markers gradually return toward baseline over 12 to 24 months. No bisphosphonate holiday protocol specific to pediatric patients has been published, but most specialists reassess the need for ongoing therapy after 2 to 3 years of treatment, particularly if the child has not sustained fractures and BMD Z-scores have normalized [34].

Special Populations Within Pediatric Under-12 Group

Infants and toddlers (under age 3). Case series document zoledronic acid use in infants as young as 3 months with OI type III, typically at doses of 0.025 mg/kg every 3 to 6 months. A 2019 case series from the Royal Children's Hospital (Melbourne) described 12 infants under 2 years who received a cumulative mean of 4.1 infusions with no cases of acute kidney injury and significant BMD improvements at 12 months [35]. This age group warrants heightened vigilance for post-infusion hypocalcemia because vitamin D sufficiency is harder to maintain in infancy and dietary calcium intake is more variable.

Children with neuromuscular disease and immobilization osteoporosis. Nonambulatory children with cerebral palsy, spinal muscular atrophy, or Duchenne muscular dystrophy develop secondary osteoporosis through mechanical unloading of the skeleton. A prospective study of 28 children (mean age 7.1 years) with cerebral palsy Gross Motor Function Classification System (GMFCS) level IV to V found that annual zoledronic acid 0.05 mg/kg IV increased distal femur BMD by 14.3% at 12 months versus 3.1% in the control group (P<0.05) [36].

Children receiving glucocorticoids for inflammatory disease. Rheumatology and nephrology services frequently encounter children on long-term prednisolone for conditions such as juvenile idiopathic arthritis, nephrotic syndrome, and inflammatory bowel disease. Rapid glucocorticoid-induced bone loss in this group can be attenuated by annual zoledronic acid, though the decision to treat must weigh baseline BMD Z-score, fracture history, and expected glucocorticoid duration [30].

Drug Interactions Relevant to Pediatric Zoledronic Acid Use

Aminoglycosides and zoledronic acid share additive hypocalcemia risk. Children receiving gentamicin or tobramycin for pulmonary infections (for example, in cystic fibrosis) should have infusions timed to avoid overlap whenever possible, and calcium and magnesium levels should be checked before infusion in this group [37].

Loop diuretics such as furosemide increase renal calcium excretion and can worsen hypocalcemia in the 24 to 48 hours after an infusion. If a child requires furosemide, it may be prudent to postpone the zoledronic acid infusion or to provide supplemental IV calcium prophylactically [38].

Thalidomide and other anti-angiogenic agents used in pediatric oncology increase ONJ risk when combined with bisphosphonates. For children receiving these agents, the bisphosphonate dose and interval should be reviewed by a multidisciplinary oncology-endocrine team [39].

Calcium and Vitamin D Supplementation Requirements

Zoledronic acid infusion without adequate calcium and vitamin D supplementation risks symptomatic hypocalcemia, which can be severe and require emergency IV calcium. Standard supplementation for children under 12 receiving IV bisphosphonates includes elemental calcium 500 to 1 to 000 mg per day (divided doses) and vitamin D 400 to 1 to 000 IU per day, adjusted based on serum 25-OH vitamin D levels [40].

The Endocrine Society's 2011 vitamin D guideline recommends that children at risk for vitamin D deficiency maintain serum 25-OH vitamin D above 20 ng/mL for bone health, with a preferred range of 40 to 60 ng/mL in children receiving potent anti-resorptive agents [41]. Supplementation should begin at least 2 weeks before the first infusion and continue uninterrupted throughout the treatment course.

If a child presents for infusion with serum 25-OH vitamin D below 15 ng/mL, the infusion should be postponed until repletion is confirmed [42]. Ergocalciferol (vitamin D2) 50 to 000 IU weekly for 6 to 8 weeks is a commonly used repletion schedule in children over 5 years, with cholecalciferol (D3) preferred for maintenance because of its longer half-life [43].